New iPad Winner:
Gitty Fishkin

$100 Amazon Gift Card Winner:
Melissa Gilhart

Please join ONS:Edge, and Spectrum Pharmaceuticals for a FREE Webinar in the comfort of your home or office and at a time that is most convenient for you!

PROGRAM OVERVIEW
This Webinar provides an excellent opportunity for you to interact directly with experienced faculty to learn management techniques for patients receiving Zevalin treatment.

LEARNING OBJECTIVES

• Develop understanding of Follicular Non-Hodgkin’s incidence and treatments
• Review key efficacy and safety data from Zevalin clinical trials
• Discuss patient eligibility criteria and administration
• Discuss patient assistance program and patient instructions for Zevalin treatment

Note: No continuing nursing education (CNE) contact hours will be awarded.

PROGRAM FACULTY

2 EASY WAYS TO RSVP TODAY!
Save Time, RSVP ONLINE
PHONE: 877-588-3343

WEBINAR DATES

Indications and Usage
ZEVALIN^® (ibritumomab tiuxetan) is a CD20-directed radiotherapeutic antibody administered as part of the ZEVALIN therapeutic regimen indicated for the treatment of patients with:

• Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL)
• Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy

Important Safety Information
WARNING: SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS, and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS

Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. Discontinue rituximab and Y-90 ZEVALIN infusions in patients who develop severe infusion reactions.

Prolonged and Severe Cytopenias: Y-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Do not administer Y-90 ZEVALIN to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve.

Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the ZEVALIN therapeutic regimen. Discontinue rituximab and Y-90 ZEVALIN infusions inpatients experiencing severe cutaneous or mucocutaneous reactions.

Dosing: The dose of the Y-90 ZEVALIN should not exceed 32.0 mCi (1184 MBq).

Leukemia and Myelodysplastic Syndrome: Among 204 patients receiving Y-90 ZEVALIN following first-line chemotherapy, two patients (1%) were diagnosed with AML within 3 years of receiving ZEVALIN.

Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) were reported in 5.2% (11/211) of patients with relapsed or refractory NHL enrolled in clinical studies and 1.5% (8/535) of patients included in the expanded-access trial, with median follow-up of 6.5 and 4.4 years, respectively. Among the 19 reported cases, the median time to diagnosis of MDS or AML was 1.9 years following treatment with the ZEVALIN therapeutic regimen; however, the cumulative incidence continues to increase.

Embryo-fetal Toxicity: May cause fetal harm if given during pregnancy.

Extravasation: Monitor for extravasation and terminate infusion if it occurs. Resume infusion in another limb.

Immunization: Do not administer live viral vaccines to patients who recently received ZEVALIN.

Laboratory Monitoring: Obtain complete blood counts (CBC) and platelet counts at least weekly.

Radionuclide Precautions: During and after radiolabeling ZEVALIN with Y-90, minimize radiation exposure to patients and to medical personnel, consistent with institutional good radiation safety practices and patient management procedures.

Creutzfeldt-Jakob Disease (CJD): The ZEVALIN therapeutic regimen contains albumin, a derivative of human blood.

Based on effective donor screening and product manufacturing processes, ZEVALIN carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of CJD also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.

Impairment of Fertility: There is a potential risk that the ZEVALIN therapeutic regimen could cause toxic effects on the male and female gonads. Effective contraceptive methods should be used during treatment and for up to 12 months following the ZEVALIN therapeutic regimen.

Nursing Mothers: Patients should be advised to discontinue nursing during and after ZEVALIN treatment.

Adverse Reactions: The most common adverse reactions of ZEVALIN are cytopenias, fatigue, abdominal pain, nausea, nasopharyngitis, asthenia, diarrhea, cough, and pyrexia. Common adverse reactions (≥40%) in clinical trials were: neutropenia, leukopenia, thrombocytopenia, anemia, infection, asthenia, musculoskeletal symptoms, and gastrointestinal symptoms. The most serious adverse reactions of ZEVALIN are prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia) and secondary malignancies.

When administered following first-line chemotherapy, grade 3/4 adverse reactions of ZEVALIN include prolonged and severe cytopenias (thrombocytopenia [51%], neutropenia [41%], leukopenia [36%], lymphopenia [18%], and anemia [5%]) and secondary malignancies. Cytopenias were more severe and more prolonged among eleven (5%) patients who received ZEVALIN after first-line fludarabine or a fludarabine containing chemotherapy regimen as compared to patients receiving non–fludarabine-containing regimens. Grade 3/4 infections occurred in 8% of ZEVALIN-treated patients and in 2% of controls and included neutropenic sepsis (1%), bronchitis, catheter sepsis, diverticulitis, herpes zoster, influenza, lower respiratory tract infection, sinusitis, and upper respiratory tract infection.

Grade 3/4 adverse reactions of ZEVALIN in relapsed or refractory NHL patients include prolonged and severe cytopenias (thrombocytopenia [63%], neutropenia [60%], anemia [17%], and ecchymosis [<1%]) and secondary malignancies. Serious infections occurred in 3% of patients (urinary tract infection, febrile neutropenia, sepsis, pneumonia, cellulitis, colitis, diarrhea, osteomyelitis, and upper respiratory tract infection). Life-threatening infections were reported in 2% of patients (sepsis, empyema, pneumonia, febrile neutropenia, fever, and biliary stent-associated cholangitis).

Please see full Prescribing Information, including BOXED WARNINGS, for ZEVALIN. Because the ZEVALIN therapeutic regimen includes the use of rituximab, please also consult Prescribing Information for rituximab.

ONS Congress Ancillary Event
Program Registration: 6 pm. Program Start: 6:30 pm

Saturday, May 5, 2012
Hilton New Orleans Riverside
Grand Ballroom C
2 Poydras Street
New Orleans, LA 70130
Registration is closed.

Hematology Regional Conference
Program Registration: 4 pm. Program Start: 4:30 pm

Pain Regional Conference
Program Registration: 4 pm. Program Start: 4:30 pm

Program Objectives:

• Review the incidence, pathophysiology, and clinical features of multiple myeloma (MM)
• Discuss M protein and other tests used for the diagnosis and evaluation of MM
• Explain MM diagnostic criteria and disease staging
• Review the pivotal trial data for VELCADE (bortezomib) that supports its use in MM patients
• Inform oncology nurses of the dosing, administration and dose modifications for VELCADE
• Discuss side effect management in patients receiving VELCADE
• Review available resources for VELCADE

 * Please note that this is not a CNE-accredited program

Two Easy Ways To RSVP:

• ONLINE: Receive instant confirmation by selecting the “Register” button to the right of the screen.
• PHONE: Call 877-588-3343 (toll-free)

You will receive a response by fax or e-mail.
Please bring your response with you for FAST CHECK-IN at the event.

Indications and Important Safety Information for
VELCADE^® (bortezomib)

INDICATIONS
VELCADE (bortezomib) is indicated for the treatment of patients with multiple myeloma. VELCADE is
indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

CONTRAINDICATIONS
VELCADE (bortezomib) is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE is contraindicated for intrathecal administration.

WARNINGS AND PRECAUTIONS
VELCADE (bortezomib) is for subcutaneous or intravenous (IV) administration only. Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered. Complete blood counts should be monitored frequently during treatment with VELCADE.

Peripheral Neuropathy, including severe cases, may occur. Patients should be monitored for symptoms and managed with dose modification or discontinuation. Patients with preexisting symptoms may experience worsening peripheral neuropathy (including ≥ grade 3). Starting with VELCADE (bortezomib) subcutaneously may be considered for patients who either have preexisting or are at high risk for peripheral neuropathy.

Hypotension can occur. Caution should be used when treating patients receiving antihypertensives, those with a history of syncope, and those who are dehydrated.

Cardiac Disorders including acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction, have been reported. Isolated cases of QT-interval prolongation have been reported. Patients with risk factors for, or existing, heart disease should be closely monitored.

Pulmonary Disorders, some fatal—including pneumonitis, interstitial pneumonia, lung infiltration, and acute respiratory distress syndrome (ARDS)—have been reported. Pulmonary hypertension in the absence of left heart failure or significant pulmonary disease has also been reported.

Gastrointestinal Adverse Events including nausea, diarrhea, constipation, and vomiting, have occurred and may require use of antiemetic and antidiarrheal medications or fluid replacement.

Thrombocytopenia/Neutropenia can occur—manage with dose and/or schedule modifications. Platelets should be monitored prior to each dose of VELCADE (bortezomib). There have been reports of gastrointestinal and intracerebral hemorrhage. Transfusions may be considered.

Patients With Hepatic Impairment: Exposure to VELCADE (bortezomib) is increased in patients with moderate or severe hepatic impairment. Start these patients at a lower dose of VELCADE and adjust after cycle 1, depending on tolerability.

Patients With Diabetes: Hypoglycemia and hyperglycemia have been reported with use of VELCADE (bortezomib). Patients may require close monitoring and adjustment of the antidiabetic medications.

Tumor Lysis Syndrome, Reversible Posterior Leukoencephalopathy Syndrome (RPLS) and Acute Hepatic Failure have been reported.

Pregnancy and Nursing: Women should avoid breastfeeding or becoming pregnant while on VELCADE (bortezomib).

DRUG INTERACTIONS:
Closely monitor patients receiving VELCADE (bortezomib) in combination with strong CYP3A4 inhibitors. Concomitant use of strong CYP3A4 inducers is not recommended.

ADVERSE REACTIONS
Previously Untreated Multiple Myeloma (MM): In the phase 3 study of VELCADE (bortezomib) administered IV with melphalan and prednisone (MP) vs MP alone, the most commonly reported adverse events were thrombocytopenia (52% vs 47%), neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), and vomiting (33% vs 16%).

Relapsed MM and Mantle Cell Lymphoma (MCL): In the integrated analysis of 1163 patients in phase 2 and 3 studies of VELCADE (bortezomib) administered IV, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), and vomiting (33%). A total of 50% of patients experienced serious adverse events (SAEs). The most commonly reported SAEs included pneumonia (7%); pyrexia (6%); diarrhea (5%); vomiting (4%); and nausea, dehydration, dyspnea, and thrombocytopenia (each 3%).

Relapsed MM Subcutaneous vs IV: In the phase 3 study of VELCADE (bortezomib) administered subcutaneously vs IV in relapsed MM, safety data were similar between the 2 treatment groups. The most commonly reported adverse events in this study were peripheral neuropathy (38% vs 53%), anemia (36% vs 35%), and thrombocytopenia (35% vs 36%). The incidence of SAEs was similar for the subcutaneous treatment group (36%) and the IV treatment group (35%). The most commonly reported SAEs were pneumonia (6%) and pyrexia (3%) in the subcutaneous treatment group and pneumonia (7%), diarrhea (4%), peripheral sensory neuropathy (3%), and renal failure (3%) in the IV treatment group.

Please click here for full Prescribing Information, also available at www.VELCADEHCP.com.

Two Easy Ways To RSVP:

• ONLINE: Receive instant confirmation by selecting the “Register” button to the right of the screen.
• PHONE: Call 877-588-3343 (toll-free)

You will receive a response by fax or e-mail.
Please bring your response with you for FAST CHECK-IN at the event.

Click to view the survey results here!

Specifically, the panelists will discuss:

• Strategies and Best Practices for Identifying NP/PA Thought Leaders
• NP Roles in Patient Education and Product Education
• Leveraging NP/PA Feedback for Educational Materials, including Ad Boards and Speaker Programs
• Current Opportunities to Incorporate NP/PA Knowledge into Business Planning

Download today!

Help your patients cope with the effects of Neuropathy.

Anemia is a common struggle for patients with cancer. 40%-60% of patients receiving chemotherapy experience the disease state, across many types of cancer and various chemotherapies.¹

Amgen and ONS:Edge have collaborated on a yearlong initiative to educate on the recognition and assessment of anemia, particularly in oncologic settings. Please join us for a dinner event that will help oncology nurses

• Understand the effect of cancer and/or chemotherapy on erythropoiesis and the resulting anemia that often develops.
• Elevate awareness of the signs and symptoms of anemia in patients with cancer.
• Appreciate impact and health consequences of anemia on the management of patients with cancer.
• Develop the ability to discuss anemia and educate patients with cancer about anemia.
• Understand and apply proactive management of anemia to improve patient functional status.

At the event, noted members of the Oncology Nursing Society will discuss how red blood cells are produced, how that process can be affected in patients with cancer and those receiving chemotherapy, how healthcare providers can define and diagnose anemia, how the disease state may affect patients, and the critical role of nurses in identifying and assessing anemia. Attendees will have an opportunity to take educational materials back to their practices.

Please join us for this unique educational opportunity.

More locations to be announced soon.

Register Now

No continuing nursing education (CNE) contact hours will be awarded. When registering for this program,
you will acknowledge that it does not offer CNE.

This program has been planned and developed in collaboration by Amgen Inc. and ONS:Edge, Inc., a subsidiary of ONS, and is sponsored by Amgen Inc.

Healthcare practitioners and providers licensed in Massachusetts, Vermont, or Minnesota: To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Massachusetts, Vermont, or Minnesota; and (2) individuals employed by prescribers in Massachusetts or Vermont who support the provision of health care. We appreciate your understanding and support.

Note. By providing your e-mail address, you are granting permission to ONS, its subsidiaries, and Amgen Inc. to communicate with you via e-mail. ONS and its affiliates will not share e-mail information with outside entities.

1. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31:2416-2432.

According to a randomly selected, blinded U.S. national survey conducted by Bard Access Systems, Inc., 93% of responding oncology nurses surveyed ranked ports as their chemotherapy delivery method of choice.

The VEINS FOR LIFE* awareness program was created to help you and other oncology clinicians:

• Understand the advantages and disadvantages of ports and other I.V. chemotherapy delivery options
• Educate patients on how ports work and how they may help to positively impact a patient’s lifestyle and comfort
• Hear from patients who share their experiences on how an implanted port has helped them in their therapy

Matching the Appropriate Access Device to Patients’ Treatment Needs

To help you decide on whether an implanted port or another vascular access device is right for your chemotherapy patients—and assist you in educating patients about available chemotherapy delivery options—visit www.VEINS4LIFE.com. A port can take your patient from the beginning to the end of treatment.

According to a randomly selected, blinded U.S. national survey conducted by Bard Access Systems, Inc., 93% of responding oncology nurses surveyed ranked ports as their chemotherapy delivery method of choice.

The VEINS FOR LIFE* awareness program was created to help you and other oncology clinicians:

• Understand the advantages and disadvantages of ports and other I.V. chemotherapy delivery options
• Educate patients on how ports work and how they may help to positively impact a patient’s lifestyle and comfort
• Hear from patients who share their experiences on how an implanted port has helped them in their therapy

Matching the Appropriate Access Device to Patients’ Treatment Needs

To help you decide on whether an implanted port or another vascular access device is right for your chemotherapy patients—and assist you in educating patients about available chemotherapy delivery options—visit www.VEINS4LIFE.com. A port can take your patient from the beginning to the end of treatment.